politics
New obesity drug from Lilly delivers major weight loss
Why this matters: political developments that affect policy direction and public trust.
An investigational obesity drug from Eli Lilly cleared important endpoints in a late-stage trial, the company said Thursday, by helping patients lose up to 30 percent of their body weight. Lilly said that a once-weekly injection of retatrutide met the primary endpoint in a phase 3 clinical trial, as
Read full story on The Hill → More top storiesAlso covered by
CNBC
Eli Lilly says next-generation weight loss drug clears crucial obesity trial
STAT News
STAT+: Lilly’s ‘triple-G’ drug leads to bariatric-surgery levels of weight loss in trial
MarketWatch
Lilly’s new experimental shot produced 28% weight loss
NY Times
Experimental Drug Yields Dramatic Weight Loss
Aggregated and edited by the Scoop newsroom. We surface news from The Hill alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop